Press Release
With reference to above subject, please find enclosed Press Release of our company titled 'Suven Life Sciences secures a Product Patent in Australia and USA'.13-06-2017
13-06-2017
Annual Investors Conference On 05Th June, 2017 (Revised)
With reference to above and further to our letter dated 01st June, 2017. We have noticed an error in our recently submitted corporate presentation to be given on 05th June, 2017 at the 'Annual Investor Conference Trinity India 2017' organized by B&K; Securities in Mumbai. Hence we are re-submitting the corrected corporate presentation with updated information about our company for the information of investors/analysts. Please find enclosed Corporate Presentation.03-06-2017
Annual Investors Conference On 01St & 2Nd June, 2017
We wish to inform you that senior management team of Suven Life Sciences is giving corporate presentation in 'Annual Investor Conference 'Centrum Corporate Connect 2017' with fund managers and analysts meet organized in Mumbai by Centrum Broking Limited on 1st & 2nd of June, 2017. Please find enclosed Corporate Presentation.30-05-2017
Suven Life begins clinical trials for major depressive disorder treatment
Suven Life Sciences in a notification to the stock exchanges on Thursday said it has initiated Phase 1 clinical trials and first dosing of a chemical entity intended for the treatment of major...25-05-2017
Press Release
With reference to above subject, please find enclosed Press Release of our company titled 'Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor (nAChRs) antagonist for Major Depressive Disorder (MDD)'.25-05-2017
Re-Submission Of Audited Standalone & Consolidated Financial Results For The Quarter & Financial Year Ended 31St March 2017
With reference to above and further to our letter dated 13th May, 2017 regarding outcome board meeting held on 13th May, 2017. We are resubmitting the Audited standalone & consolidated Financial Results of the Company for the quarter and financial year ended 31st March, 2017 as per schedule III of the Companies, Act, 2013.19-05-2017
Fixes Book Closure for AGM
Suven Life Sciences Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 11, 2017 to August 14, 2017 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 14, 2017.16-05-2017
Q4 result update: Suven Life Sciences
Hyderabad based pharma company Suven Life Sciences has reported a 7.8% increase in its standalone net profits, which rose to Rs. 40.06 crore in the Q4 ended March 2017, up from Rs 37.2 crore in the same period last year. Net sales of the firm were up 3.3% to Rs. 174.99 crore in the quarter. Suven Life Sciences, which has been granted product patents in international markets for treatments of neurogenerative diseases, said it remained optimistic about growth for the coming FY18 quarter, and said its board has declared and paid an interim dividend of Re1 per share for FY17. The company reported a consolidated net profit for the entire FY of Rs 87.18 crore, compared to Rs 71.8 crore in the previous year. Suven's share price has been trending above all its SMAs in the week before results.14-05-2017
Suven Life Sciences Q4 net profit up 7.8% at Rs40 crore
Suven Life Sciences' net sales rose 3.3% to Rs174.99 crore during the quarter against Rs169.37 crore in the year-ago period13-05-2017
Outcome of Board Meeting
We have submitted Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and financial year ended 31st March, 2017 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 together with Auditors' Report and Declaration by Chairman & CEO of the Company under Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, today. This is to inform you that in the financial...13-05-2017